Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Oberarzt/-ärztin, Klinik für Neurologie
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
-
SoSe 2023
-
WiSe 2022
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Cancer-related cognitive impairment in patients with non-central nervous system malignancies : An overview for oncology providers from the MASCC Neurological Complications Study GroupIn: Supportive Care in Cancer, Jg. 29, 2021, Nr. 6, S. 2821 – 2840
-
Prospective evaluation of health care provider and patient assessments in chemotherapy-induced peripheral neurotoxicityIn: Neurology, Jg. 97, 2021, Nr. 7, S. E660 – E672DOI, Online Volltext (Open Access)
-
Periphere und zentrale Neurotoxizität nach TumortherapieIn: Tägliche Praxis, Jg. 63, 2020, Nr. 3, S. 475 – 490
-
Periphere und zentrale Neurotoxizität nach TumortherapieIn: Pädiatrische Praxis, Jg. 94, 2020, Nr. 1, S. 69 – 84
-
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicityIn: Journal of the Peripheral Nervous System, Jg. 24, 2019, Nr. 1, S. 111 – 119DOI, Online Volltext (Open Access)
-
Periphere und zentrale Neurotoxizität nach TumortherapieIn: Internistische Praxis, Jg. 61, 2019, Nr. 2, S. 313 – 328
-
Response assessment of meningioma : 1D, 2D, and volumetric criteria for treatment response and tumor progressionIn: Neuro-Oncology, Jg. 21, 2019, Nr. 2, S. 234 – 241DOI (Open Access)
-
Prophylaxe und Therapie der chemotherapieinduzierten PolyneuropathieIn: Best Practice Onkologie, Jg. 13, 2018, Nr. 4, S. 214 – 225
-
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningiomaIn: Neuro-Oncology, Jg. 18, 2016, Nr. 3, S. 401 – 407
-
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideIn: Neuro-Oncology, Jg. 18, 2016, Nr. 11, S. 1529 – 1537
-
Periphere Neurotoxizität : Präventive DosismodifikationIn: Der Onkologe, Jg. 21, 2015, Nr. 4, S. 311 – 317
-
Central nervous system lymphoma in a patient with mycosis fungoidesIn: Neuro-Oncology, Jg. 16, 2014, Nr. Suppl 2, S. ii61
-
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: : Secondary analysis of data from the CI-PeriNomS studyIn: Journal of the Peripheral Nervous System, Jg. 19, 2014, Nr. 2, S. 127 – 135DOI, Online Volltext (Open Access)
-
Management options for established chemotherapy-induced peripheral neuropathyIn: Supportive Care in Cancer, Jg. 22, 2014, Nr. 8, S. 2281 – 2295
-
Neuromuscular complications after hematopoietic stem cell transplantationIn: Supportive Care in Cancer, Jg. 22, 2014, Nr. 9, S. 2337 – 2341
-
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity : two sides of the same coinIn: Annals of Oncology, Jg. 25, 2014, Nr. 1, S. 257 – 264
-
Treatment of multiple myeloma: Thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathyIn: Oncology Research and Treatment, Jg. 37, 2014, Nr. 9, S. 506 – 513
-
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutationIn: Neurology, Jg. 81, 2013, Nr. 17, S. 1515 – 1522
-
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)In: European Journal of Cancer (EJC), Jg. 49, 2013, Nr. 13, S. 2910 – 2918
-
The chemotherapy-induced peripheral neuropathy outcome measures standardization study : From consensus to the first validity and reliability findingsIn: Annals of Oncology, Jg. 24, 2013, Nr. 2, S. 454 – 462
-
Visual field defect related to temozolomideIn: Neuro-Oncology, Jg. 15, 2013, Nr. Suppl. 3, S. 116
-
New-Onset Parkinson Syndrome After Liver TransplantationIn: Transplantation, Jg. 94, 2012, Nr. 8, S. e56 – e57
-
Management der Polyneuropathie beim Multiplen Myelom unter der Therapie mit Bortezomib : Empfehlungen aus klinischen ErfahrungenIn: TumorDiagnostik & Therapie, Jg. 32, 2011, Nr. 3, S. 153 – 158
-
Treatable Bortezomib-related peripheral neuropathy in multiple myelomaIn: Journal of the Peripheral Nervous System, Jg. 16, 2011, Nr. Suppl. 3, S. 68
-
Electrically evoked nociceptive potentials for early detection of diabetic small-fiber neuropathyIn: European Journal of Neurology, Jg. 17, 2010, Nr. 6, S. 834 – 841
-
Neurologic complications in adult living donor liver transplant patients : An underestimated factor?In: Journal of Neurology, Jg. 257, 2010, Nr. 2, S. 253 – 258DOI (Open Access)
-
Lack of neuroprotection by an ACTH (4-9) analogue : A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphomaIn: Journal of Cancer Research and Clinical Oncology, Jg. 130, 2004, Nr. 3, S. 153 – 160
-
Predominantly motor polyneuropathy following brentuximab vedotin
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 319DOI (Open Access) -
Physician-assessed and petient-reported outcome measuresin chemotherapy-induced sensory peripheral neurotoxicity : two sides of the same coin
Meeting of the Peripheral Nerve Society, June 29–July 3, 2013, Saint–Malo, France,In: Journal of the Peripheral Nervous System. Hoboken: Wiley, Jg. 18, 2013, Nr. S2, S. 3 – 4 -
Provider perceptions of clinical neuropathy examination usefulness
Meeting of the Peripheral Nerve Society, June 29–July 3, 2013, Saint–Malo, France,In: Journal of the Peripheral Nervous System. Hoboken: Wiley, Jg. 18, 2013, Nr. 2, S. 42 – 43 -
An investigator-initiated monocentric phase I dose escalation trial of temsirolimus and irinotecan (TEMIR) in patients with relapsing glioblastoma multiforme (reGBM)
48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 30, 2012, Nr. 15, Suppl., 2086